Niagen Bioscience

Niagen Bioscience company information, Employees & Contact Information

Niagen Bioscience (NASDAQ:NAGE), founded in 1999 and formerly known as ChromaDex, is the global authority on nicotinamide adenine dinucleotide (NAD+), dedicated to advancing healthy-aging science. Our world-renowned scientists collaborate with independent investigators from leading universities and research institutions worldwide to explore the full potential of NAD+, a vital coenzyme found in every cell that declines with age and everyday stressors. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, Niagen Bioscience is the innovator behind Niagen® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. Our ingredient is backed by 35+ human clinical trials and 400+ peer-reviewed studies, making it one of the world's most extensively researched and validated NAD+ precursors. We offer two distinct product lines: Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States*, clinically proven to increase NAD+ levels and help people transform the way they age (available at www.truniagen.com) Niagen® Plus, our premium pharmaceutical-grade NAD+ therapy featuring Niagen™ IV and injectables, available exclusively at clinics with a prescription (www.niagenplus.com) Our robust patent portfolio protects NR and other NAD+ precursors. As pioneers in NAD+ technology, we continue to demonstrate our commitment to excellence, innovation, and integrity through our two California locations (Tustin and Westwood) and our premier research Laboratory & Innovation Center in Longmont, CO. Visit www.niagenbioscience.com for press releases, news, and financial information. Interested in joining our team? Explore career opportunities at https://jobs.lever.co/niagenbioscience +Based on the top selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace. (1/1/24-12/31/24)
Looking for a particular Niagen Bioscience employee's phone or email?

Niagen Bioscience Questions

News

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Business Wire

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Business Wire

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide - Yahoo Finance

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide Yahoo Finance

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth - Business Wire

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth Business Wire

Earnings call transcript: Niagen Bioscience Q1 2025 sales surge, stock rises - Investing.com

Earnings call transcript: Niagen Bioscience Q1 2025 sales surge, stock rises Investing.com

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference - Business Wire

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference Business Wire

Niagen Bioscience signs exclusive licence deal for PD therapy - Pharmaceutical Technology

Niagen Bioscience signs exclusive licence deal for PD therapy Pharmaceutical Technology

Niagen Bioscience: A Great Company Suffering From Stock Dilution - Seeking Alpha

Niagen Bioscience: A Great Company Suffering From Stock Dilution Seeking Alpha

Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Intrinsic Value Is Potentially 91% Above Its Share Price - Yahoo Finance

Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Intrinsic Value Is Potentially 91% Above Its Share Price Yahoo Finance

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook - Business Wire

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook Business Wire

Statutory Profit Doesn't Reflect How Good Niagen Bioscience's (NASDAQ:NAGE) Earnings Are - Yahoo Finance

Statutory Profit Doesn't Reflect How Good Niagen Bioscience's (NASDAQ:NAGE) Earnings Are Yahoo Finance

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+ - Business Wire

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+ Business Wire

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York - Business Wire

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York Business Wire

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs Business Wire

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder - Business Wire

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder Business Wire

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook - Business Wire

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook Business Wire

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide - Business Wire

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide Business Wire

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - Business Wire

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science Business Wire

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms Business Wire

Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance

Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models Yahoo Finance

Earnings call transcript: Niagen Bioscience Q2 2025 earnings beat expectations - Investing.com

Earnings call transcript: Niagen Bioscience Q2 2025 earnings beat expectations Investing.com

Niagen Bioscience notches partial win in ad challenge - SupplySide Supplement Journal

Niagen Bioscience notches partial win in ad challenge SupplySide Supplement Journal

Niagen Bioscience says it will profit from NMN news - SupplySide Supplement Journal

Niagen Bioscience says it will profit from NMN news SupplySide Supplement Journal

Niagen Bioscience Inc (NAGE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Niagen Bioscience Inc (NAGE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... Yahoo Finance

Niagen Bioscience: High Conviction, High Expectations (NASDAQ:NAGE) - Seeking Alpha

Niagen Bioscience: High Conviction, High Expectations (NASDAQ:NAGE) Seeking Alpha

Niagen Bioscience, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:NAGE) 2025-08-19 - Seeking Alpha

Niagen Bioscience, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:NAGE) 2025-08-19 Seeking Alpha

ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal

ChromaDex changes name to Niagen Bioscience to home in on healthy aging SupplySide Supplement Journal

Niagen Bioscience: Overbought After Rally (NASDAQ:NAGE) - Seeking Alpha

Niagen Bioscience: Overbought After Rally (NASDAQ:NAGE) Seeking Alpha

Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling - TipRanks

Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling TipRanks

Niagen Bioscience secures exclusive rights for Parkinson’s therapy - Longevity.Technology

Niagen Bioscience secures exclusive rights for Parkinson’s therapy Longevity.Technology

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Business Wire

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 Business Wire

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway - BioSpace

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway BioSpace

ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries - NutraIngredients.com

ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries NutraIngredients.com

Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap dropped US$129m last week; individual investors who hold 33% were hit as were institutions - simplywall.st

Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap dropped US$129m last week; individual investors who hold 33% were hit as were institutions simplywall.st

ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - Citeline News & Insights

ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ Citeline News & Insights

Top Niagen Bioscience Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant